Periodically
a list of items stacks up that reflect small bits of information relevant to public
health workers. Based on viewing
numbers, such reviews are well received – so here is another one in celebration of topping 7000 views.
Cancer statistics
Annually, the Canadian Cancer Society has released the Canadian Cancer
Statistics. Top of the incidence list
for females and males respectively is breast and prostate cancer. Second and third for both is lung and
colorectal cancer. Lung cancer remains
the top killer both genders with breast second for females, colorectal third
for females and second for males, and prostate the third leading male
killer. Pancreatic cancers are fourth
leading cause of death for both genders.
While all cancer age standardized incidence rates have
remained relatively stable, the numbers diagnosed each year increase as the
population grows and ages. Mortality
rates have been decreasing substantially - but even so the numbers of persons
dying from cancer continues to increase for the same reasons. The monograph does a good job of explaining
this anomaly.
So the cautionary notes:
The incidence of non-Hodgkin’s Lymphoma, Kidney, Liver and thyroid cancers
are going up. With thyroid in females being
the most rapidly increasing. Lymphomas
can be secondary to immunosuppression including treatment for other illnesses
or primary due to environmental exposures.
Liver cancers are likely secondary to carriage rates of Hep B and C.
Overall the annual publication is a good read and well worth
staying in tune with the changing face of cancer in the country. This year’s iteration is found at Cancer
stats 2012.
Breastfeeding: As Time
magazine stimulates the breastfeeding dialogue with discussion of the socially
acceptable upper age to feed Star
editorial on Time magazine , it was noteworthy to see a good quality review
of the value of exclusive breastfeeding to 6 months of age. Science playing catch up to society. Breastfeeding literature
review.
MS and CCVI treatment: Suffers of multiple sclerosis and their
families have no doubt followed the chronic cerebrovascular insufficiency
(CCVI) debate closely. DrPHealth spoke
to this in August 2011 if
its too good to be true, it probably isn't. Last week the FDA issued a warning about the
risks of CCVI alluding that the risks
exceed the benefits. While some trials
are still in progress, expect more bad news for MS suffers that have been
placed on the roller coaster of hope. FDA
alert on CCVI
No comments:
Post a Comment